Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia

Stopped early · Phase 2

Conditions studied: Chronic Lymphocytic Leukemia

In brief

This study will determine whether or not Lenalidomide improves effectiveness of treatment for chronic lymphocytic leukemia following chemotherapy with two drugs commonly used to treat the disease (bendamustine and rituximab).

Key facts

Study ID

NCT01465230

Run by

Yale University

People needed

2

Starts

2012-03-01

Expected to finish

2013-11-01

Last updated by the study team

2014-10-23

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Previous induction treatment with bendamustine and rituximab
• 18 or more years of age
• chronic lymphocytic leukemia
• ECOG performance status less than or equal to 2
• Absolute neutrophile count more than 1,000
• Platelet count more than 70,000

You may not qualify if…

• Serious medical condition that would prevent treatment with lenalidomide
• Evidence of tumor lysis syndrome
• Any prior treatment with lenalidomide

Where it is running

• Yale Cancer Center — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.